CI-1044

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 524728

CAS#: 197894-84-1

Description: CI-1044 is a novel phosphodiesterase 4 inhibitor. It inhibits LPS-induced TNF-alpha production in whole blood in chronic obstructive pulmonary disease (COPD) patients.

Chemical Structure

img
CI-1044
CAS# 197894-84-1
Instruction

Theoretical Analysis

MedKoo Cat#: 524728
Name: CI-1044
CAS#: 197894-84-1
Chemical Formula: C23H19N5O2
Exact Mass: 397.15
Molecular Weight: 397.430
Elemental Analysis: C, 69.51; H, 4.82; N, 17.62; O, 8.05

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: CI-1044; CI 1044; CI1044; UNII-O4T475XIIY; PD-189659.

IUPAC/Chemical Name: (R)-N-(9-amino-4-oxo-1-phenyl-3,4,6,7-tetrahydro-[1,4]diazepino[6,7,1-hi]indol-3-yl)nicotinamide

InChi Key: XGXOSJSGDNPEEF-NRFANRHFSA-N

InChi Code: InChI=1S/C23H19N5O2/c24-17-11-15-8-10-28-20(15)18(12-17)19(14-5-2-1-3-6-14)26-21(23(28)30)27-22(29)16-7-4-9-25-13-16/h1-7,9,11-13,21H,8,10,24H2,(H,27,29)/t21-/m0/s1

SMILES Code: Nc1cc2CCN3C(=O)[C@H](NC(=O)c4cccnc4)N=C(c5ccccc5)c(c1)c23

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 397.43 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Pruniaux MP, Lagente V, Ouaged M, Bertin B, Moreau F, Julien-Larose C, Rocher MN, Leportier C, Martin B, Bouget A, Dubuit JP, Burnouf C, Doherty AM, Bertrand CP. Relationship between phosphodiesterase type 4 inhibition and anti-inflammatory activity of CI-1044 in rat airways. Fundam Clin Pharmacol. 2010 Feb;24(1):73-82. doi: 10.1111/j.1472-8206.2009.00725.x. Epub 2009 Jul 24. PubMed PMID: 19650853.

2: Hanton G, Sobry C, Daguès N, Provost JP, Le Net JL, Comby P, Chevalier S. Characterisation of the vascular and inflammatory lesions induced by the PDE4 inhibitor CI-1044 in the dog. Toxicol Lett. 2008 Jun 10;179(1):15-22. doi: 10.1016/j.toxlet.2008.03.009. Epub 2008 Mar 25. PubMed PMID: 18485625.

3: Ouagued M, Martin-Chouly CA, Brinchault G, Leportier-Comoy C, Depincé A, Bertrand C, Lagente V, Belleguic C, Pruniaux MP. The novel phosphodiesterase 4 inhibitor, CI-1044, inhibits LPS-induced TNF-alpha production in whole blood from COPD patients. Pulm Pharmacol Ther. 2005;18(1):49-54. Epub 2004 Nov 23. PubMed PMID: 15607127.